OLFML3 and neoplasm: We extensively described that several important tumor-growth-promoting cell types are affected by anti-OLFML3 antibody treatment (blood and lymphatic endothelial cells, pericytes, and TAMs) that are altogether linked during tumor development, blood vessel formation, and immune cell infiltration (Figure 7).